Comprehensive analysis of TCR repertoire in COVID-19 using single cell sequencing.


Journal

Genomics
ISSN: 1089-8646
Titre abrégé: Genomics
Pays: United States
ID NLM: 8800135

Informations de publication

Date de publication:
03 2021
Historique:
received: 02 10 2020
revised: 20 12 2020
accepted: 27 12 2020
pubmed: 1 1 2021
medline: 9 3 2021
entrez: 31 12 2020
Statut: ppublish

Résumé

T-cell receptor (TCR) is crucial in T cell-mediated virus clearance. To date, TCR bias has been observed in various diseases. However, studies on the TCR repertoire of COVID-19 patients are lacking. Here, we used single-cell V(D)J sequencing to conduct comparative analyses of TCR repertoire between 12 COVID-19 patients and 6 healthy controls, as well as other virus-infected samples. We observed distinct T cell clonal expansion in COVID-19. Further analysis of VJ gene combination revealed 6 VJ pairs significantly increased, while 139 pairs significantly decreased in COVID-19 patients. When considering the VJ combination of α and β chains at the same time, the combination with the highest frequency on COVID-19 was TRAV12-2-J27-TRBV7-9-J2-3. Besides, preferential usage of V and J gene segments was also observed in samples infected by different viruses. Our study provides novel insights on TCR in COVID-19, which contribute to our understanding of the immune response induced by SARS-CoV-2.

Identifiants

pubmed: 33383142
pii: S0888-7543(20)32083-8
doi: 10.1016/j.ygeno.2020.12.036
pmc: PMC7833309
pii:
doi:

Substances chimiques

Receptors, Antigen, T-Cell 0

Types de publication

Comparative Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

456-462

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Références

World J Gastroenterol. 2020 May 21;26(19):2286-2293
pubmed: 32476793
J Immunol. 2006 Sep 15;177(6):3893-902
pubmed: 16951352
J Immunol. 2016 Jun 15;196(12):5005-13
pubmed: 27183615
Lancet Respir Med. 2020 Apr;8(4):420-422
pubmed: 32085846
Trends Pharmacol Sci. 2020 Aug;41(8):518-530
pubmed: 32576386
Int J Oncol. 2016 Jun;48(6):2247-56
pubmed: 27098221
Nat Med. 2020 Jul;26(7):1070-1076
pubmed: 32514174
Immunity. 2016 Oct 18;45(4):917-930
pubmed: 27760342
Cancer Immunol Res. 2015 Apr;3(4):305-12
pubmed: 25847967
Cell Host Microbe. 2020 Jun 10;27(6):879-882.e2
pubmed: 32359396
J Immunol. 2005 Nov 1;175(9):6123-32
pubmed: 16237109
Clin Infect Dis. 2020 Nov 19;71(16):2052-2060
pubmed: 32307550
Nat Med. 2020 Jun;26(6):842-844
pubmed: 32398875
Nat Commun. 2019 Jul 26;10(1):3353
pubmed: 31350389
Protein Cell. 2014;5(8):603-15
pubmed: 24866699
Front Immunol. 2018 Nov 22;9:2729
pubmed: 30524447
Nat Rev Immunol. 2013 May;13(5):309-20
pubmed: 23598650
Immunol Rev. 2013 Sep;255(1):197-209
pubmed: 23947356
Nucleic Acids Res. 2020 Jan 8;48(D1):D1057-D1062
pubmed: 31588507
Proc Natl Acad Sci U S A. 1991 Oct 15;88(20):8987-90
pubmed: 1833769
PLoS Comput Biol. 2015 Nov 25;11(11):e1004503
pubmed: 26606115
Nat Rev Immunol. 2012 Nov;12(11):749-61
pubmed: 23080391
Trop Med Int Health. 2020 Mar;25(3):278-280
pubmed: 32052514
Lancet Infect Dis. 2020 May;20(5):533-534
pubmed: 32087114
Lancet Infect Dis. 2020 Apr;20(4):398-400
pubmed: 32113510
Lancet Infect Dis. 2020 Apr;20(4):400-402
pubmed: 32113509
Proc Natl Acad Sci U S A. 2019 Apr 30;116(18):8995-9001
pubmed: 30992377
Nat Rev Immunol. 2015 Aug;15(8):486-99
pubmed: 26205583
Curr Opin Immunol. 2008 Feb;20(1):119-25
pubmed: 18207719
JAMA. 2020 Aug 4;324(5):460-470
pubmed: 32492084
Nat Biotechnol. 2020 Aug;38(8):970-979
pubmed: 32591762
Cell Discov. 2020 May 4;6:31
pubmed: 32377375
Nat Commun. 2016 Apr 04;7:11153
pubmed: 27040081
Signal Transduct Target Ther. 2020 Aug 14;5(1):156
pubmed: 32796814
Science. 2020 May 1;368(6490):493-497
pubmed: 32213647
Immunol Rev. 2019 Sep;291(1):8-25
pubmed: 31402501
Immunity. 2020 Apr 14;52(4):583-589
pubmed: 32259480
J Immunol. 2011 Jun 15;186(12):7039-49
pubmed: 21555537

Auteurs

Pingping Wang (P)

School of Life Science and Technology, Harbin Institute of Technology, Harbin 150000, China.

Xiyun Jin (X)

School of Life Science and Technology, Harbin Institute of Technology, Harbin 150000, China.

Wenyang Zhou (W)

School of Life Science and Technology, Harbin Institute of Technology, Harbin 150000, China.

Meng Luo (M)

School of Life Science and Technology, Harbin Institute of Technology, Harbin 150000, China.

Zhaochun Xu (Z)

School of Life Science and Technology, Harbin Institute of Technology, Harbin 150000, China.

Chang Xu (C)

School of Life Science and Technology, Harbin Institute of Technology, Harbin 150000, China.

Yiqun Li (Y)

School of Life Science and Technology, Harbin Institute of Technology, Harbin 150000, China.

Kexin Ma (K)

School of Life Science and Technology, Harbin Institute of Technology, Harbin 150000, China.

Huimin Cao (H)

School of Life Science and Technology, Harbin Institute of Technology, Harbin 150000, China.

Yan Huang (Y)

School of Life Science and Technology, Harbin Institute of Technology, Harbin 150000, China.

Guangfu Xue (G)

School of Life Science and Technology, Harbin Institute of Technology, Harbin 150000, China.

Shuilin Jin (S)

School of Mathematics, Harbin Institute of Technology, Harbin 150000, China.

Huan Nie (H)

School of Life Science and Technology, Harbin Institute of Technology, Harbin 150000, China. Electronic address: nh1212@hit.edu.cn.

Qinghua Jiang (Q)

School of Life Science and Technology, Harbin Institute of Technology, Harbin 150000, China; Key Laboratory of Biological Big Data (Harbin Institute of Technology), Ministry of Education, China. Electronic address: qhjiang@hit.edu.cn.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH